back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2025-07-29 14:30 Tx date 2025-07-21 |
$HBP
Helix BioPharma Corp. |
Mehrling, Thomas Jorg Heinrich
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$17,170
+17,000 vol $1.01 each |
47,000 | |
| Filed 2025-07-29 14:29 Tx date 2025-07-17 |
$HBP
Helix BioPharma Corp. |
Mehrling, Thomas Jorg Heinrich
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$29,700
+30,000 vol $0.99 each |
30,000 | |
| Filed 2025-07-29 14:24 Tx date 2025-03-05 |
$HBP
Helix BioPharma Corp. |
Mehrling, Thomas Jorg Heinrich
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-05-22 12:41 Tx date 2025-05-16 |
$HBP
Helix BioPharma Corp. |
Mehrling, Thomas Jorg Heinrich
5 - Senior Officer of Issuer
Holder: Laevoroc Chemotherapy AG (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$8,981,445
+9,454,153 vol $0.95 each |
9,454,153 | |
| Filed 2025-05-22 12:37 Tx date 2025-03-05 |
$HBP
Helix BioPharma Corp. |
Mehrling, Thomas Jorg Heinrich
5 - Senior Officer of Issuer
Holder: Laevoroc Chemotherapy AG (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-05-22 12:37 Tx date 2025-05-16 |
$HBP
Helix BioPharma Corp. |
Mehrling, Thomas Jorg Heinrich
5 - Senior Officer of Issuer
Holder: Laevoroc Immunology AG (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$10,977,322
+11,555,076 vol $0.95 each |
11,555,076 | |
| Filed 2025-05-22 12:32 Tx date 2025-03-05 |
$HBP
Helix BioPharma Corp. |
Mehrling, Thomas Jorg Heinrich
5 - Senior Officer of Issuer
Holder: Laevoroc Immunology AG (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-05-22 12:30 Tx date 2025-05-16 |
$HBP
Helix BioPharma Corp. |
Laevoroc Medical AG CH
3 - 10% Security Holder of Issuer
Holder: Laevoroc Chemotherapy AG (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
9,454,153 | ||
| Filed 2025-05-22 12:28 Tx date 2025-05-16 |
$HBP
Helix BioPharma Corp. |
Laevoroc Medical AG CH
3 - 10% Security Holder of Issuer
Holder: Laevoroc Immunology AG (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
11,555,076 | ||
| Filed 2025-05-22 12:21 Tx date 2025-05-16 |
$HBP
Helix BioPharma Corp. |
Laevoroc Immunology AG
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
11,555,076 | ||
| Filed 2025-05-22 12:13 Tx date 2025-05-16 |
$HBP
Helix BioPharma Corp. |
Laevoroc Chemotherapy AG
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
9,454,153 | ||
| Filed 2024-08-21 20:09 Tx date 2024-08-16 |
$HBP
Helix BioPharma Corp. |
LAUBE, MALGORZATA IRENA
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-400,000 vol |
100,000 | |
| Filed 2024-08-21 20:07 Tx date 2024-08-16 |
$HBP
Helix BioPharma Corp. |
Leszczynski, Jerzy Alfred
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-1,666,675 vol |
416,669 | |
| Filed 2024-08-21 20:06 Tx date 2024-08-16 |
$HBP
Helix BioPharma Corp. |
Leszczynski, Jerzy Alfred
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-400,000 vol |
100,000 | |
| Filed 2024-08-21 20:03 Tx date 2024-08-16 |
$HBP
Helix BioPharma Corp. |
Grabski, Janusz Bernand
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-400,000 vol |
100,000 | |
| Filed 2024-08-21 19:57 Tx date 2024-08-16 |
$HBP
Helix BioPharma Corp. |
ANTAS, JACEK MAREK
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-2,553,280 vol |
638,320 | |
| Filed 2024-08-21 19:56 Tx date 2024-08-16 |
$HBP
Helix BioPharma Corp. |
ANTAS, JACEK MAREK
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-10,000,000 vol |
2,500,000 | |
| Filed 2024-08-21 19:48 Tx date 2024-08-16 |
$HBP
Helix BioPharma Corp. |
Varshney, Praveen
5 - Senior Officer of Issuer
Holder: Varshney Capital Corp. (Indirect Ownership)
|
Options
37 - Stock split or consolidation
|
-268,000 vol |
67,000 | |
| Filed 2024-08-21 19:47 Tx date 2024-08-16 |
$HBP
Helix BioPharma Corp. |
Varshney, Praveen
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-4,532,000 vol |
1,133,000 | |
| Filed 2024-07-26 13:55 Tx date 2024-07-26 |
$HBP
Helix BioPharma Corp. |
Wilczewski, Jerzy
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-3,295,388.94
-14,327,778 vol $0.23 each |
19,617,153 |